Japanese

　HOME > Greetings




　KUMON Hiromi
　 Director, Innovation Center Okayama for Nanobio-targeted Therapy

　　As we look forward to the scientific and technological revolution leading
　　contemporary Japan to further heights in the 21st century, the most important
　　keyword is “innovation” and it will be realized through the promotion of sciences
　　and technologies that will directly influence society in general and make people
　　feel benefited from them. Deliberately choosing cancer treatment, one of the
　　foremost issues in our rapidly aging country, as a target therapeutic area,
　　Okayama University’s program to “form a center for the creation of nanobio-
　　targeted therapy through interdisciplinary research” is committed to achieving
　　a patient-friendly targeted therapy in cooperation with our seven partner
　　enterprises, through an optimal integration of revolutionary remedies, new drug
　　delivery systems (DDSs), and advanced labeling techniques (molecular imaging).

　　With the average life expectancy of the Japanese reaching 80 years, innovative
　　technologies to ensure patients’ quality of life (QOL) are highly anticipated.
　　Minimally invasive medical management that enables early diagnosis and
　　treatment of affected regions with pinpoint accuracy is one example of such a
　　technology.Our goal is to transform people’s lifestyles by creating new values
　　after deconstruction that will accelerate a paradigm shift (structural changeover).
　　By applying research findings to the prevention of cancer, we are determined
　　to make ICONT a research center that improves the QOL in our aging society.

　　For Japan to take a global leading position, we need to create a framework for
　　proactive research efforts in advanced fusion areas at medical institutions
　　affiliated with universities; translational research, via exploratory clinical studies,
　　is indispensable for the creation and discovery of new drugs and medical
　　systems. Here at ICONT, we are committed to becoming an institution that is
　　capable of performing both basic and clinical research. A new generation of
　　interdisciplinary biotechnology researchers and engineers also is being trained
　　to support further research and development.

　　Through our programs, we hope to become a top-tier Asia-based international
　　research center, with the ultimate goal of applying the fundamental techniques
　　of nanobio-targeted therapy to other areas, including infectious diseases and
　　environmental management. We encourage different opinions and comments
　　from various fields, especially from the industrial sector. Your continued support
　　is most appreciated.


　

KUMON Hiromi
Director, Innovation Center
Okayama for Nanobio-
targeted Therapy